DDrare: Database of Drug Development for Rare Diseases

56. ベーチェット病
［臨床試験数：68，薬物数：87（DrugBank：31），標的遺伝子数：36，標的パスウェイ数：113］

Searched query = "Behcet disease", "Behçet disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 2387066; 3400935113276; 8699505952864; AIN457; APREMILAST; Adalimumab; Allogeneic Stem Cell Transplant; Alpha interferon; Anakinra; Apremilast; Apremilast (CC-10004); Autologous Stem Cell Transplant; Autologous Stem Cell Transplantation; BFGF; CANAKINUMAB; CC; CC-10004; Calcium; Canakinumab; Colchicine; Cyclophosphamide; Cyclosporin; Cyclosporin A; Cyclosporine; Cyclosporine Pill; Cytotoxic Combination; Daclizumab; Dextrose; Entecavir; Etanercept; Etanercept, Methotrexate, Prednisolone; Flucinolone acetonide; GEVOKIZUMAB; GSK1070806; Gevokizumab; Golimumab; Golimumab (GOL); Hemay005; Hydroxychloroquine; IL-2; INTERLEUKIN 2; Ilaris; Infliximab; Interferon Alfa-2A; Interferon alfa; Interferon alfa-2a; Interferon alpha-2a; Interferon-alpha2a; Interleukin 2; Intravitreal Infliximab; J1081; Low-dose IL-2; Methotrexate; Methylorednisolone; Otezla; Other: dextrose water 5%; Other: serum levels of angiogenin, bFGF, VEGF; Pentoxifylline; Prednisolone; Radiation: Diode laser 980nm&100 mWatt; Remicade; Remicade 100 mg; RhumAb to Il-17A (IgG1-k-class); Rituximab; Roferon-A; Roferon-A 3miu; Roferon-A, 3miu; Roferon-A, 4.5miu; Roferon-A, 6miu; Rosuvastatin; Rosuvastatin calcium 40mg; S78989; STELARA; Stelara; Subcutaneous Ustekinumab; TA-650; Thalidomide; Tocilizumab; Tocilizumab (TCZ); Topical Pentoxifylline Gel (Vehicle +PTX); Triamcinolone; Triamcinolone Acetonide; Ustekinumab; Veldona; Veldona,; Water; XOMA 052

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	ChiCTR1900027147	2020-01-01	2019-11-02	Efficacy and safety of adalimumab in Behcet's disease-related uveitis	Efficacy and safety of adalimumab in Behcet's disease-related uveitis	Behcet's disease-related uveitis	1:Adalimumab;	State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University	NULL	Pending			Both	1:30;	Phase 4	China
2	JPRN-UMIN000012469	2013/12/02	02/12/2013	Comparison of Adalimumab and Steroid in Intestinal Behcet's disease	Comparison of Adalimumab and Steroid in Intestinal Behcet's disease - Castle Study	Intestinal Behcet's disease	Subcutaneous injection of adalumumab with 160mg at 0 week, 80mg at 2 weeks and 40mg every other week after at 4 weeks continuously. Oral administration of prednisolone with 0.6mg/kg/day during from 1 to 2 weeks, and tapering off until 12 weeks with decreasing dosage 5mg/kg/week approximately	Castle Study Group	NULL	Recruiting	15years-old	Not applicable	Male and Female	50	Not selected	Japan
3	NCT01243671 (ClinicalTrials.gov)	October 2010	17/11/2010	A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease	A Multi-Center Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease	Intestinal Behçet's Disease	Biological: Adalimumab	AbbVie (prior sponsor, Abbott)	Eisai Co., Ltd.	Completed	15 Years	N/A	All	20	Phase 3	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

ChiCTR1900027147

2020-01-01

2019-11-02

Efficacy and safety of adalimumab in Behcet's disease-related uveitis

Behcet's disease-related uveitis

1:Adalimumab;

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University

NULL

Pending

Both

1:30;

Phase 4

China

JPRN-UMIN000012469

2013/12/02

02/12/2013

Comparison of Adalimumab and Steroid in Intestinal Behcet's disease

Comparison of Adalimumab and Steroid in Intestinal Behcet's disease - Castle Study

Intestinal Behcet's disease

Subcutaneous injection of adalumumab with 160mg at 0 week, 80mg at 2 weeks and 40mg every other week after at 4 weeks continuously.
Oral administration of prednisolone with 0.6mg/kg/day during from 1 to 2 weeks, and tapering off until 12 weeks with decreasing dosage 5mg/kg/week approximately

Castle Study Group

NULL

Recruiting

15years-old

Not applicable

Male and Female

Not selected

Japan

NCT01243671
(ClinicalTrials.gov)

October 2010

17/11/2010

A Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease

A Multi-Center Study of Adalimumab in Japanese Subjects With Intestinal Behçet's Disease

Intestinal Behçet's Disease

Biological: Adalimumab

AbbVie (prior sponsor, Abbott)

Eisai Co., Ltd.

Completed

15 Years

N/A

All

Phase 3

Japan